News

GLP-1

Rare GLP1R variants linked to less weight loss on semaglutide in 17 carriers, with a non-significant gap on tirzepatide in 19

By Monica O’Reilly

Published · Updated

Gloved hands place a small tube among colored sample tubes on ice in a black bowl on a laboratory bench
DNA samples prepared for PCR. National Cancer Institute archive photo, 2020.

A Nature Metabolism study linked genetic data to health records for 13,725 adults treated with semaglutide or tirzepatide. Only 33 carried a rare damaging GLP1R variant. Carriers on semaglutide lost less weight than matched non-carriers. Carriers on tirzepatide lost weight close to the non-carrier average. The carrier groups were small, so the findings are early.

Who was studied

Researchers used the Helix Research Network, which links exome sequencing to health records across 13 North American health systems. They identified adults with a BMI of 25 or higher who started semaglutide or tirzepatide in routine care, then followed weight for six to 12 months.

Rare variants in GLP1R, the gene for the receptor both drugs act on, occur in roughly 0.1% to 0.4% of people in population cohorts. In this treated group, 33 adults carried a qualifying variant. Each carrier was matched to non-carriers by drug, dose, sex, diabetes status, baseline BMI and follow-up time.

Semaglutide: a large gap in a small group

Among 17 carriers taking semaglutide, average weight loss was 2.4% of body weight. Matched non-carriers lost 8.8%. Fifteen of the 17 carriers lost less than their matched non-carriers did.

Tirzepatide: a smaller, non-significant gap

Among 19 carriers taking tirzepatide, average weight loss was 13.3%, against 15.2% in matched non-carriers. That difference was not statistically significant, and 11 of 19 carriers lost less than their matches. With 19 people, a modest real gap could still exist.

The test for a difference between the two drugs was statistically significant. Tirzepatide also acts on the GIP receptor, and the authors suggest this second target may help when GLP-1 receptor signaling is impaired. The study did not test that mechanism directly.

Variants in the second target

Carriers of rare damaging variants in GIPR, the gene for the GIP receptor, had weight loss close to their matches. Sixty of 63 GIPR carriers were matched. The results did not differ by drug.

What limits the findings

People were not randomly assigned to a drug, so the semaglutide and tirzepatide groups differ in ways matching may not capture. Weights and adherence came from health records. The authors note that the carrier group was mostly of European genetic similarity and that carrier numbers were small, especially within each drug.

What it means for patients

Rare GLP1R variants are uncommon, so they explain the response of very few people. Genetic testing for this is not part of routine prescribing. Anyone who has lost less weight than expected on semaglutide can discuss dose, adherence and alternatives with their prescriber. One study of this size does not establish who should switch drugs.

Sources (2)

This is news reporting and not medical advice.